Search Results

Your search for David M. O’Malley, MD, and Antonio Castaneda, MD,David M. O’Malley, MD, and Antonio Castaneda, MD matches 2 pages

Showing 1 - 2

By David M. O’Malley, MD, and Antonio Castaneda, MD / September 10, 2020 - Supplement: Gynecologic Cancers Almanac

Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both poly (ADP-ribose) polymerase (PARP) inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG...

gynecologic cancers

By David M. O’Malley, MD, and Antonio Castaneda, MD / May 10, 2020

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

Based on multiple phase III prospective trials, there is evidence that both PARP inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG 218, ICON7, SOLO-1, PRIMA,...

Nov

Today In Oncology

Search Results

Your search for David M. O’Malley, MD, and Antonio Castaneda, MD,David M. O’Malley, MD, and Antonio Castaneda, MD matches 2 pages

Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer

PARP Inhibitors in Maintenance Treatment for Advanced Ovarian Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC